Valaciclovir Studies
Select the study ID number to view the trial summary
| Study ID | Phase | Title |
| 104689 | IV | Post-Marketing Clinical Study of Valaciclovir Hydrochloride Tablets –Single Oral Dose Study in Hemodialysis Patients |
| HS2100181 | IV | An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3 |
| HS2100273 | IV | A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes |
| HS2100275 | IV | An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valaciclovir 1g Once Daily vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Subjects |
| HS240017 | IV | A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Daily Suppressive Therapy With VALTREX™ on the Rate of HSV Shedding in Subjects With Recurrent Genital Herpes |
| HS240018 | IV | A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes |
| HS240021 | IV | A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes |
| PREV123 | IV | Multicentre randomised trial comparing two strategies for the episodic use of valaciclovir, alone or combined with suppressive treatment in immunocompetent patients with recurrent genital herpes |
| VAL R24 | IV | A Double-Blind Study Comparing Two Doses of Valacyclovir HCL for the Treatment of Uncomplicated Herpes Zoster in Immunocompromised Patients 18 Years of Age and Older |
| VAL R94 | IV | An Open-Label Pilot Study of valacyclovir (VALTREX) 2000 mg BID for One Day in the Episodic Treatment of Recurrent Genital Herpes |
| VALF1005 | IV | Safety Follow-Up of the Association Valaciclovir-Mycophenolate Mofetil and Evaluation of the Potential Pharmacokinetic Interaction Between Valaciclovir and Mycophenolate Mofetil When They are Co-Administered in Renal Transplant Recipients |
| VALF1007 | IV | A pharmacokinetic study to evaluate the intra-ocular penetration of aciclovir following single, oral dose of valaciclovir in subjects undergoing cataract surgery. |
| VLX103596 | IV | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Infection |
| VLX105832 | IV | The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection |
| WEUK-347 | IV | The Safety of Valacyclovir Among Severely Immunocompromised Patients with HIV-1/HSV-2 Co-Infection. |
| 123-007 | III | A Comparative Trial of Valaciclovir and Aciclovir for the Suppression of Ano-Genital Herpes Infections in HIV-Infected Patients |
| 123-008 | III | A Study to Investigate the Efficacy and Safety of Valaciclovir in the Treatment of Recurrent Ano-Genital Herpes in HIV-Infected Patients |
| 123-014 (ACTG204) | III | A Randomised Double-Blind Trial of Valaciclovir (BW256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (<100CD4+ Lymphocytes) |
| 123-016 | III | 123-016: A Double-blind, Multi-centre Study Comparing Oral Valaciclovir and Aciclovir for the Suppression of CMV Infection and Disease Following Allogeneic Bone Marrow Transplantation |
| 123-026 | III | A Comparative Trial of Valaciclovir With Aciclovir and Placebo for the Suppression of Recurrent Genital Herpes Infections in Immunocompetent Patients |
| 123-033 | III | A randomized, double blind, placebo controlled cross over trial to compare valacyclovir HCl and acyclovir for suppression of subclinical herpes simplex virus shedding |
| 123-037 | III | A Randomised, Double-Blind, Controlled Study of Valaciclovir for the Suppression of Recurrent Genital Herpes Simplex Virus Infection in Immunocompetent Patients |
| 123-044 | III | Pharmacokinetics of valaciclovir in late pregnancy |
| 123-304 | III | Zoster ophthalmicus in immunocompetent patients |
| 123-310 | III | A double-blind, multicenter study comparing valacyclovir HCL with famciclovir for the treatment of uncomplicated herpes zoster in immunocompetent patients 50 years of age and older |
| HS2101951 | III | An Open-Label, Uncontrolled Pharmacokinetic and Clinical Evaluation Study of Valaciclovir Hydrochloride in Children with Chickenpox. |
| HS230017 | III | An open-label, randomized, crossover study to determine subject treatment preference and efficacy of once daily valacyclovir 500 mg suppression therapy versus valacyclovir 500 mg twice daily treatment for recurrent genital HSV infections |
| HS230018 | III | An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects |
| HS230027 | III | A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Reduction of the Length of Cold Sore Episodes |
| HS230028 | III | A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention/Blockage of the Progression of Cold Sore Lesion Development |
| HS2A3005 | III | An Open-Label, Pilot Study to Estimate the Effect on Subject Survival and the Safety of CMV Prophylaxis with IV Acyclovir Followed by Valacyclovir Hydrochloride or Ganciclovir in Allogeneic Bone Marrow Transplant Recipients |
| HS2A4004 | III | A Comparison of Oral VALTREX 500mg Twice Daily for Three or Five Days for Treatment of Recurrent Genital Herpes |
| HS2AB3009 | III | A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus (HSV) Transmission in Heterosexual Couples (Double-Blind Phase and Open-Label Suppression Phase) |
| HS2B1001 | III | A study to compare the intraocular penetration of valaciclovir and aciclovir following multiple dose oral administration to patients undergoing cataract surgery. |
| HS2B3010 | III | A Randomized, Double-Blind Study to Compare Valaciclovir 500mg Twice Daily Given for Three Days With the Standard Five Day Course as Episodic Treatment for Recurrent Genital Herpes |
| HSV-003(JP) | III | Phase III Study of Valaciclovir Hydrochloride Tablets in Immunocompetent Patients With Herpes Simplex Virus Infections – Double-Blind Comparative With Aciclovir Tablets |
| P66/H73-005 | III | An International, Double-Blind, Controlled Trial Comparing Oral Acyclovir to Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients 50 Years of Age or Older |
| P66/H73-006 | III | A Multicenter, Double-Blind, Placebo-Controlled Trial Evaluating Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients Less Than 50 Years Old |
| P66/H73-012 (Pharmacokinetics) | III | Pharmacokinetic Analysis: Oral 256U87 Safety, Pharmacokinetics, and Prophylaxis of Cytomegalovirus Infection and Disease in Renal Allograft Recipients |
| P66/H73-012 (CMV Seronegative Recipients) | III | Oral 256U87 (Valaciclovir) Safety, Pharmacokinetics and Suppression of Cytomegalovirus Infection and Disease in Renal Allograft Recipients |
| P66/H73-012 (CMV Seropositive Recipients) | III | Oral 256U87 (Valaciclovir) Safety, Pharmacokinetics and Suppression of Cytomegalovirus Infection and Disease in Renal Allograft Recipients |
| P66-H73-003 (123-003) | III | A Comparative Trial of Valacyclovir and Acyclovir for the Treatment of First-Episode Genital Herpes Infection |
| U87TH-04 | III | Clinical Effect of Valaciclovir Hydrochloride (256U87) Tablets in Patients With Genital Herpes |
| VALF 3002 | III | Multicentre, randomised, open-label study to compare the efficacy and safety of valaciclovir oral route and aciclovir intravenous route, to treat zoster in immunodeficient patients. |
| VAL-R19 | III | A Single-Center, Open-Label Study of the Safety and Pharmacokinetics of Valacyclovir in Children with Epstein-Barr Virus Illness |
| VAL-R56 | III | Acyclovir Concentrations in Human Breast Milk After Valaciclovir Administration |
| 123-031 | II | A Pilot, Randomized, Double-Blind Study to Investigate the use of Valaciclovir for the Prophylaxis of CMV Infection in Recipients of a Heart or Single Lung Transplant |
| 123(H73)-013-V | I | The Pharmacokinetics of Valaciclovir and Acyclovir After Oral Administration of a Single Dose of Valaciclovir to Patients With Cirrhosis and Healthy Volunteers |
| 123-034 | I | Report of the Pharmacokinetics of Aciclovir and Digoxin Following Administration of Digoxin and Valaciclovir Alone and in Combination to Healthy Volunteers |
| 123-038 | I | Evaluation of the Effect of an Aluminium Hydroxide and Magnesium Hydroxide Containing Antacid on the Pharmacokinetics of Valaciclovir and Acyclovir Following a Single Oral Dose of Valaciclovir |
| H73-020-V | I | The Effects of Probenecid and Cimetidine on the Pharmacokinetics of Valaciclovir and its Metabolite Acyclovir in Healthy Male Volunteers |
| HS210909 | I | Report of a Study to Evaluate the Bioequivalence of Single Doses of an Investigational Formulation of Valaciclovir Compared to the Standard Valaciclovir Tablet in Healthy Volunteers |
| HS210914 | I | An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children |
| HS210915 | I | An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with HSV infection |
| HS210916 | I | An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with VZV infection |
| HS240016 | I | CSF Penetration of Acyclovir and its Metabolites After High Dose Valacyclovir Administration |
| HS2B4001 | I | A Pharmacokinetic Study to Compare Aciclovir Plasma Exposures Attained with IV Zovirax® 5mg/kg t.d.s and Oral Valtrex® 1000mg t.d.s. in Neutropenic Non-HIV Patients |
| HS2B4005 | I | An Investigation of the Steady-State Pharmacokinetics of Oral Valacyclovir in Immunocompromised Children |
| P66-09 (123-009) | I | Single-Dose Pharmacokinetics and Safety of Valaciclovir in Volunteers with End-Stage Renal Disease |
| P66-10 | I | Pharmacokinetics and Safety of Acyclovir and Valaciclovir Following Single and Multiple Oral Administration of Valaciclovir in Geriatric Volunteers With and Without Concomitant Diuretic Therapy |
| VALF1004 | I | Safety Follow-Up of the Association Valaciclovir –Tacrolimus and Evaluation of the Potential Pharmacokinetic Interaction Between Valaciclovir and Tacrolimus When They are Co-Administered in Renal Transplant Recipients |
| VALF1006/HS210911 | I | A Randomised, Open-Label, Cross-Over, Single Dose Study to Evaluate the Pharmacokinetic Interaction Between Aciclovir 800mg and Mycophenolate Mofetil 1000mg and Between Valaciclovir 2000mg and Mycophenolate Mofetil 1000mg in Healthy Volunteers |